@article{0fb40ab8fc944dcab1f256e98b0946b6,
title = "Ustekinuma b for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study",
keywords = "Ustekinumab, Crohn's disease, real-world, ICC Registry, INFLAMMATORY-BOWEL-DISEASE, REAL-WORLD EXPERIENCE, SUBCUTANEOUS USTEKINUMAB, MAINTENANCE THERAPY, MULTICENTER, VEDOLIZUMAB, OUTCOMES, SAFETY",
author = "T. Straatmijer and V.B.C. Biemans and F. Hoentjen and {de Boer}, N.K.H. and A.G.L. Bodelier and G. Dijkstra and {van Dop}, W.A. and J.J.L. Haans and J.M. Jansen and P.W.J. Maljaars and {van der Marel}, S. and B. Oldenburg and C.Y. Ponsioen and M.C. Visschedijk and {de Vries}, A.C. and R.L. West and {van der Woude}, C.J. and M. Pierik and M. Duijvestein and {van der Meulen-de Jong}, A.E.",
year = "2021",
month = nov,
day = "1",
doi = "10.1093/ecco-jcc/jjab081",
language = "English",
volume = "15",
pages = "1920--1930",
journal = "Journal of Crohn's & Colitis",
issn = "1873-9946",
publisher = "Oxford University Press",
number = "11",
}